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Abstract
Background: Antibodies constitute a powerful tool to study protein function, protein localization and protein-
protein interactions, as well as for diagnostic and therapeutic purposes. High-throughput antibody development
requires faster methodologies with lower antigen consumption.
Results: Here, we describe a novel methodology to select human monoclonal recombinant antibodies by
combining in vitro protein expression, phage display antibody libraries and antibody microarrays. The application of
this combination of methodologies permitted us to generate human single-chain variable fragments (scFvs) against
two proteins: green fluorescent protein (GFP) and thioredoxin (Trx) in a short time, using as low as 5 μg of purified
protein. These scFvs showed specific reactivity against their respective targets and worked well by ELISA and
western blot. The scFvs were able to recognise as low as 31 ng of protein of their respective targets by western
blot.
Conclusion: This work describes a novel and miniaturized methodology to obtain human monoclonal
recombinant antibodies against any target in a shorter time than other methodologies using only 5 μg of protein.
The protocol could be easily adapted to a high-throughput procedure for antibody production.
Keywords: scFv antibodies, in vitro protein expression, phage display, antibody microarrays
Background
A crucial challenge of the proteome era is to use the
genome information for a better understanding of pro-
tein expression, protein cellular distribution and func-
tionality discovery not only in normal but also in
pathological processes [1,2]. Antibody development
against every human protein is a prerequisite to improve
this knowledge. Several high-throughput alternatives
have been developed to generate antibodies to the entire
proteome [3-5]. The Human Protein Atlas initiative
(http://www.proteinatlas.org/) [3,4], the Sanger Institute
Antibody Atlas Database, the NCI Clinical Proteomics
[5], the HUPO human antibody initiative (http://www.
hupo.org/research/hai/) [6], and several EU-funded con-
sortia (ProteomeBinders, AffinityProteome, Affinomics
[7-9]; http://www.proteomebinders.org) are all good
examples of these alternatives.
The production of mAbs and/or rabbit antibodies
requires large amounts of antigens, it is time-consuming
due to the immunization step of the animals and, in the
case of mAbs, the screening and clone selection can
take from 6 months to 1 year [10].The development of
recombinant antibodies in single-chain Fv (scFv) formats
is a good alternative to obtain high-affinity antibodies
against any target without time-consuming immuniza-
tion [11-14]. The affinity of scFvs for their targets might
be comparable to that of mAbs or pAbs and in some
cases even higher [15]. As a general rule, scFvs possess
several advantages in comparison to IgG or Fabs such as
higher tissue penetrance and more rapid clarification
[16,17]. Moreover, antibody phage display, M13-based
human libraries, is becoming particularly useful for the
production and development of antibodies for immu-
notherapy in different diseases [18-21]. In vitro phage
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to the complete human proteome, but the selections are
still carried out manually [8,9,22]. Screening of phage
display antibody libraries is constrained by the necessity
of having considerable amounts of antigen, at least 0.1-
0.5 mg of protein for the whole procedure (selection,
screening and validation).
The necessity of having significant amounts of the
purified target protein, not only for production and
selection but also for the screening of antibodies, is one
of the main problems to develop antibodies, and consti-
tutes a major bottleneck associated to all three alterna-
tives above described [10]. Despite progress in
automation, protein expression is a limiting step to get
toxic, difficult-to-express or membrane proteins. Rapid,
efficient, and cost-effective protein expression and puri-
fication strategies are required for the production of
antibodies against any target, trying to minimize at the
same time, the amount of required protein.
Cell-free expression is a powerful and flexible technol-
ogy. New advances in this technology have faced the
higher demand for high-throughput protein synthesis.
These advances include the use of cell-extracts from dif-
ferent backgrounds (prokaryotic or eukaryotic), modula-
tion of the reducing environment for the correct
production of disulfide bonds, incorporation of deter-
gents, lipid bilayers or other non-lipoprotein particles
for the expression of membrane proteins and, finally,
the automation of the procedure [23-26]. Furthermore,
cell-free systems offer several advantages over traditional
cell-based expression methods, which include lower sen-
sitivity to product toxicity and suitability for high-
throughput strategies, because of reduced reaction
volumes and processing time. Recent improvements in
translation efficiency have resulted in yields comparable
to cell-based expression systems for difficult-to-express
proteins [27-30].
Bacterial, wheat germ and reticulocyte lysates have been
used as in vitro expression systems inaw i d ev a r i e t yo f
strategies [31]. Rapid Translation System (RTS) [32], a
bacterial-based commercially available cell-free protein
expression system, has been used for the high-throughput
expression of inner and outer membrane proteins from
Anaplasma marginale [33]. In 2000, the Riken Structural
Genomics Initiative (Japan) reported the bacterial based
cell-free protein expression production of about 25% of
randomly chosen mouse cDNA clones with yields higher
than 0.1 mg/ml [34]. Since then, several developments
have significantly improved the yield of in vitro expressed
proteins in the range of milligrams of protein per mL of
reaction mix [27,28,35,36]. Another interesting initiative is
the “human protein factory”, for the expression of human
proteins using the wheat-germ in vitro protein expression
system and Gateway technology [24]. The authors
reported a 97% success rate of protein expression over
13364 human proteins. Among them, they detected solu-
ble proteins in 12682 out of 13364 clones [24]. There have
been other successful high-throughput initiatives based on
in vitro protein expression, with yields up to 6 mg/mL,
which have been applied for protein arrays, nuclear mag-
netic resonance and crystallization studies [37-39].
Regarding the use of low amounts of protein, the micro-
array format is particularly useful for low consumption
and automation. Antibody arrays were initially designed to
capture and detect simultaneously multiple analytes with
high affinity and selectivity in human biological samples
(plasma, serum, tissue ...) in order to study variations
between biological statuses [5]. We have explored the use
of this proteomic technique for testing scFv antibody
l i b r a r i e sa g a i n s td i f f e r e n ta n t i g e n sa tt h es a m et i m ei n
order to identify specific scFvs, increasing the throughput
of the screening step with minimal requirements of pro-
tein. In this report, we propose a novel methodology to
develop scFv antibodies using human phage display anti-
body libraries in a short time (no more than four weeks)
with only 5 μg of protein. Furthermore, this method could
be automated in a high-throughput format to obtain “anti-
bodies on demand” against any target, taking advantage of
cell-free protein expression, antibody phage display and
scFv antibody microarrays.
Results
Production of human scFvs against cell-free expressed
antigens
The cDNAs-encoding GFP and Trx were cloned into
pIVEX and pET32b plasmids, respectively, and used for
the in vitro transcription/translation reactions. The cell-
free expression yielded between 5-10 μg of purified pro-
tein per 50 μL RTS reaction. The purity and homogene-
ity of the expressed proteins were confirmed by SDS-
PAGE and western blot using 10 μl of RTS reaction
(Figure 1A, B).
Proteins were immobilized on the TALON™ magnetic
beads and used to get antibodies by phage display. After
extensive washing with PBS, TALON Dynabeads
® were
divided in five tubes containing 10 μLo fb e a d s ,o n ef o r
each of the four rounds of selection with the libraries
and the fifth one for Alexa Fluor 647-protein labelling.
A remarkable phage enrichment for both proteins was
observed by ELISA after 3 or 4 rounds of biopanning
(Figure 1C).
scFv antibody microarray preparation
A total of 192 scFvs from each specific antigen selection
were recovered from the 3
rd and 4
th round of selection,
purified from the periplasmic fraction of HB2151 E. coli
cells and directly printed in duplicate onto FAST nitro-
cellulose slides (Figure 2A)[40-42]. Although some scFv
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ent clones, a correct printing pattern was detected, indi-
cating adequate printing conditions (Figure 2B). The
amount of scFv printed in the array was determined by
printing serial 1:10 dilutions of previously reported anti-
gastrin TA4 scFv at 0.5 μg/ml to construct a regression
line [40]. Then, we used the median of the fluorescence
signal of the scFvs in the regression line to get the
amount of scFvs printed in the array. Approximately 12
pg of antibodies were printed in each spot of the array.
T h eq u a l i t yo ft h es c F va n t i b o d ym i c r o a r r a yw a sc o n -
firmed by the absence of cross contamination between
successive spots. All positivec o n t r o l sa sw e l la sb u f f e r
spots showed the correct reactivity. The intra-assay
reproducibility was assessed by comparing the results
between the two replicas printed within the same chip
for each clone and gave an R
2 = 0.9311 (Figure 2C).
Evaluation of specific scFvs in microarray format
Evaluation of specific scFvs against GFP and Trx was
performed by using scFv antibody microarrays. Cell-free
expressed and purified GFP and Trx proteins were
directly labeled with 647Alexa Fluor at 1 μg/mL to be
probed in the antibody microarrays (Figure 3). In our
microarrays, 384 recombinant scFvs were simultaneously
tested. The scFvs obtained against each other antigen
were also used as controls for the selection of highly-
specific scFvs that did not show cross-reactivity to other
antigen (Figure 3A,C).
Figure 1 Cell-free protein expression and characterization.A )
Cell free GFP and Trx expression and purification by TALON™
Dynabeads
® was assessed by SDS-PAGE and Coomassie Blue
staining. U, unpurified total protein extract. P, protein purified with
TALON™ Dynabeads
®. B) Western blot analysis of the proteins by
using peroxidase-labeled anti-His. U, unpurified total protein extract.
P, Proteins purified with TALON™ Dynabeads
®. C) ELISA
characterization of the polyclonal phages after different rounds of
biopanning. A peroxidase-labeled anti-M13 was followed by TMB
incubation to develop the signal. His-tagged BSA and GST were
used as negative controls.
Figure 2 Printing conditions and scFv antibody microarrays
reproducibility. A) Printing map of a microarray comprising 384
scFvs against GFP or Trx. Controls used in the assay were: red box,
mAb anti-T7Tag, 1:10 diluted. Yellow box, mAb anti-T7Tag 1:100
diluted. Blue box, crude Trx (top) or GFP (bottom) RTS extract 1:10
diluted. Grey box, printing buffer. Green box, TA4 anti-gastrin17
scFv; from right to left 1:10, 1:100, 1:1000 and 1:1000 dilutions. B) A
representative image of a microarray probed with an anti-c-myc
antibody to assess the correct printing of the scFvs. For detecting c-
myc antibody, slides were incubated with Alexa Fluor 555-labeled
goat anti-mouse IgG antibodies. White spots indicate a saturation of
the green signal intensity. C) scFvs were spotted in duplicate onto
FAST nitrocellulose coated slides to verify the intra-assay
reproducibility. Replicated spots showed a uniform intensity either
visually or by GenePix analysis. The two intensity values for each
clone were quantified and plotted to assess the intra-array
reproducibility.
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Figure 3 Screening of specific scFvs using a microarray format. Cell free-expressed proteins were labeled with 647 AlexaFluor and incubated
with GFP- and Trx-specific scFvs microarrays to identify highly specific scFv binders. E. coli-expressed proteins were used as a control. A) Selection
of GFP-specific scFvs. Left, performance of the microarray with cell free-expressed 647-labeled GFP or Trx as control. Right, performance of the
microarray with E. coli expressed proteins followed by a polyclonal anti-GFP or a monoclonal anti-Flag and by AlexaFluor 555 labeled antibodies
gave a green fluorescent signal. White boxes: 10 scFv antibodies against GFP showing at least 3-fold higher fluorescence signal than the control
Trx values. Red boxes: scFvs showing non-specific binding for GFP. B) Anti-GFP scFv clones were tested by ELISA using GFP and GST to compare
the microarray technology with ELISA screening. C) Selection of Trx-specific scFvs. Left, performance of the microarray with cell free-expressed
647-labeled Trx or GFP as control. Right, performance of the microarray with E. coli-expressed proteins followed by a polyclonal anti-GFP
antibody or a monoclonal anti-Flag and by AlexaFluor 555 labeled antibodies. White boxes: 8 reactive scFv antibodies detected by antibody
microarrays against Trx showing at least 3-fold higher fluorescence signal than the control GFP values. Red boxes: scFvs showing non-specific
binding for Trx. D) Anti-Trx scFv clones were tested by ELISA using Trx, GST-His6 tagged and BSA to compare the performance of the microarray
technology to identify Trx scFv binders with ELISA screening. Green arrows indicate the top three scFvs that gave the highest microarray signal
for GFP or Trx and were further validated by other immunological techniques.
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tem, we used also GFP and Trx proteins expressed in E.
coli, followed by a fluorescent labelled antibody (Figure
3A,C). Although signal intensity was usually stronger
and background fluorescence was lower for the E. coli-
derived proteins, a similar reactivity pattern was
observed for the cell-free Alexa647-labeled purified pro-
tein (red) or the E. coli-expressed GFP and Trx (green),
indicating an adequate performance of the expression
system and the microarray screening.
To check the effect of a potential scFv denaturation
during printing and to demonstrate the utility of the
screening by antibody microarrays, we tested all the
scFv binders for each antigen by ELISA. A comparable
number of scFv binders were found by ELISA and by
antibody microarrays. By antibody microarrays, we
found 10 GFP-specific scFvs with 3-fold higher signals
than the negative controls (microarray incubated with
T r x ) .B yE L I S A ,w ef o u n d1 3s c F v sw i t ha tl e a s t2 - f o l d
higher signals than the negative controls (Figure 3B),
obtaining a 62% of coincidence (8 GFP-specific scFvs)
between ELISA and antibody microarray. Regarding Trx
scFv binders, we found by ELISA 8 scFvs with 2-fold
higher signals than the negative controls (Figure 3D). By
antibody microarrays (Figure 3C) we also found 8 Trx-
specific scFvs with 3-fold higher signals than the nega-
tive controls (microarray incubated with GFP). Indeed,
we were able to detect 6 Trx scFv binders by both tech-
niques, with a 75% coincidence between both techni-
ques. Collectively, these data support the use of
antibody microarray screening to identify highly-specific
scFv antibodies as an alternative to conventional ELISA.
Characterization of the selected scFvs
To confirm the value of the scFvs obtained by antibody
microarray screening, we characterized the three scFvs
showing strongest reactivity against each in vitro-
expressed antigen. These scFvs were tested by ELISA to
compare their reactivity against the in vitro-expressed
proteins and the E. coli-expressed proteins. The results
were similar for the three anti-GFP scFvs (GFP-H6,
GFP-C10 and GFP-A10) (Figure 4A, B). The two scFvs
that showed strong recognition by antibody microarrays
were also the best for ELISA. However, although Trx-
A1 and Trx-E8 worked well in both assays (Figure 4A,
B), Trx-E10 scFv showed a lower correlation between
antibody microarrays and ELISA values.
The 6 scFvs selected (three per antigen) recognised
their target proteins by western blot analysis, without
cross-reactivity (Figure 4C). Indeed, most of the scFvs
were able to detect as low as 31.3 ng of protein by wes-
tern-blot, indicating the suitability of the scFvs for this
technique. Indeed, Trx-A1 and Trx-E8 only showed 2-4
times lower sensitivity to Trx than M2 mAb to the Flag
epitope (Figure 4C). Finally, the six scFvs were
sequenced. All the scFvs-encoding DNA sequences were
different (data not shown). The scFvs displayed signifi-
cant variability not only in the CDRs but also in the fra-
mework as a consequence of the naïve origin of the
Mehta libraries.
Discussion
Antibodies are used to study protein expression and
localization within a tissue, cell or organelle, protein-
protein interactions or protein function [1,4,14,43,44].
Moreover, antibodies have multiple clinical uses for the
diagnosis and treatment of diseases [5,20,21,45].
To study and characterize the human proteome, it is
necessary to establish high-throughput methodologies for
testing multiple antibodies against different proteins
[10,12,13,46]. Here, we propose a new methodology to
raise antibodies to any potential protein target: “antibo-
dies on demand”. This is a fast method to obtain recom-
binant human monoclonal antibodies against any
antigen. Only 5 μg of protein were necessary to perform
t h ew h o l ep r o c e d u r e ,s i n c ew et o o ka d v a n t a g eo fm e t h -
odologies that require minimal amounts of protein: i) in
vitro protein expression and purification, ii) antibody
phage display and iii) scFv antibody microarray screening.
This approach avoids the production of considerable
amounts of protein necessary for both, the immuniza-
tion and the screening steps, which usually are the bot-
tlenecks for antibody development. In our hands, a
dedicated person could produce antibodies in about 4
weeks, calculating 5 working days per week: i) 3 days for
amplification, DNA purification and in vitro protein
expression and purification by TALON™ Dynabeads
®,
ii) 8 days for three-four rounds of biopanning by phage
display and E. coli amplification, iii) 3-4 days for print-
ing and screening of scFv antibody microarrays and iv)
3-4 days for production and verification of the scFv
results (Figure 5).
This methodology could be adapted to a high-
throughput system. Indeed, all the techniques used in
this report have been previously adapted to high-
throughput assays [8,9,22,34,47,48]. One main advantage
of our approach relies on the utilization of in vitro bac-
terial cell-free expression. Different reports support this
expression strategy, because yields as low as 5 μg of pro-
tein were enough to get antibodies. Proteins with recov-
ery yields below this amount could be scaled up in vitro
as much as necessary to obtain the 5 μgo fp r o t e i n
required for this approach.
Initially, cell-free expression was restricted by several
limitations, especially for the expression of transmem-
brane proteins or proteins rich in disulfide bonds. How-
ever, advances in the in vitro technology have minimized
these limitations by including several components, like
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ratios and protein disulfide isomerase for the correct
folding and production of proteins presenting disulfide
bonds or different detergents and lipid bilayers for the
expression of membrane proteins [25,26,49-52].
The microarray format for antibody screening shows
different advantages: i) consumes minimal amounts of
proteins, ii) is very sensitive, iii) improves the specificity,
and iv) is suitable for high-throughput screening of anti-
bodies. At the same time that we identified a recombi-
nant antibody to a particular protein, a global-binding
profile is simultaneously generated because different
antibodies produced against different proteins are
printed in the same array, permitting the selection of
only highly specific, non cross-reactive antibodies. With
our microarray settings, we could print up to 4800 spots
in a high-density antibody format per slide. Since, only
192 scFvs were tested in duplicate per antigen, we could
significantly increase the multiplexing of this methodol-
ogy by testing antibodies against 12 targets simulta-
neously in the same slide.
Moreover, the use of recombinant antibodies in
microarray format did not alter significantly scFvs bind-
ing properties after printing. It has been described that
only a fraction of antibodies work well after printing on
the surface of microarrays, due to the loss of activity by
denaturation or degradation during printing and array
storage. To explore the fact that we could have been
losing 60-80% of total scFvs due to denaturation in our
antibody microarrays [5,53], we decided to test all the
scFvs by ELISA to compare the performance of the
microarray and verify the usefulness of antibody micro-
arrays for identification of scFv binders. Interestingly, we
were able to identify a similar number of scFv binders
by both screenings with a coincidence of 62 and 75%
for GFP and Trx, respectively. These data support the
utilization of antibody microarrays for the screening
step, while consuming only 0.5 μg of 647 AlexaFluor
protein.
Remarkably, scFvs were prepared by using a naïve
scFv phage display library displaying multiple scaffolds
(frameworks), avoiding the use of scFv antibody libraries
Figure 4 Application of the scFvs in ELISA and WB. A) Selected scFvs were tested by ELISA against the cell free-expressed proteins, E. coli-
derived GFP and scFv-Trx 3xFlag proteins, using BSA and GST as negative controls. B) Intensity of the fluorescence signal of the GFP or Trx-
specific scFvs in comparison to a scFv control signal or buffer obtained from the normalized data of the microarrays after incubation with
647Alexa Fluor labelled-GFP, 647Alexa Fluor labelled-Trx or anti c-myc followed by 555 AlexaFluor anti-mouse IgG, respectively. C) Different
amounts of GFP or scFv-Trx were separated by SDS-PAGE and transferred to nitrocellulose membranes to determine the sensitivity of the anti-
GFP and the anti-Trx scFvs (1:10 diluted) as primary antibodies. They were followed by an anti-c-myc tag and peroxidase-labeled anti-mouse IgG
antibody, respectively. An anti-His6 mAb or an anti-M2 Flag mAb were used as positive controls to detect the target proteins.
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usually possess one fixed scaffold [48].
Conclusion
We have developed a new and fast method to produce
scFv antibodies by using only 5 μg of cell-free expressed
protein and a naive scFv antibody library in combination
with an antibody microarray format for screening. The
scFvs were useful for different applications (ELISA, anti-
body microarrays and western blot). This antibody pro-
duction technology could be especially applicable to
“difficult-to-express” or toxic proteins, or when the
amount of available protein might be a limiting step.
Methods
In vitro protein expression, purification and
characterization
Plasmids pET32b-Trx or pIVEX-GFP were used in the cell
free transcription/translation system to produce Trx or
GFP, respectively. Plasmid DNA (1 μg) was ethanol preci-
pitated and used as template for in vitro transcription/
translation using the Rapid Translation System
® (RTS) kit
(Roche Applied System). RTS reactions containing DNA
template in 50 μLo fs o l u t i o n( 1 2μL E.coli lysate, 10 μL
reaction mix, 12 μL amino acids, 1 μL methionine,
5 μL reconstitution buffer and 1 μgo fD N Ai n1 0μL
RNAse-free water) were incubated at 30°C for 6 h at
300 rpm in a Thermomixer (Eppendorf). 10 μlR T S
reaction for GFP and Trx was exclusively used to ana-
lyze the quality of the expressed and purified proteins
with TALON™ Dynabeads
® b yC o o m a s s i eB l u es t a i n -
ing of 10% SDS-PAGE gels or, alternatively, by immu-
noblotting using an anti-His6-tag antibody (0.3 μg/ml,
Roche). One RTS reaction was used to determine the
enrichment of the biopanning procedure and to verify
the scFv binding by ELISA.
BSA (Sigma), E. coli-expressed GFP-His6 (GE) and an
irrelevant scFv fused to Trx (3xFlag, His6-tagged) were
used as control proteins in this study. GST-His6 and scFv-
Trx (3xFlag, His6) proteins were produced in E. coli
according to established procedures [54]. Briefly, pET41b
(Novagen) containing GST-cDNA and pSANG10-3F con-
taining the cDNA encoding the scFv-Trx were used to
transform BL21 (DE3) E. coli cells. His6-tagged proteins
were then expressed and purified by affinity chromatogra-
phy on a HiTrap chelating column (GE Healthcare).
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Figure 5 Scheme of the full procedure. Methodology and time schedule to produce antibodies on demand by using in vitro protein
expression, phage display libraries and antibody microarrays.
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libraries
Human scFv Mehta libraries (a kind gift of Wayne Mar-
asco, Dana-Farber Cancer Center. USA) were used for
scFv production [55,56]. Mehta scFvs contain a c-myc
tag for detection and purification. Phage display selec-
tions were performed using the proteins attached to
TALON Dynabeads. Briefly, cell-free expressed proteins
were attached to TALON™ Dynabeads through the
His6 tag by incubating 40 μL of the RTS reaction with
50 μL of magnetic beads. Five equal aliquots were pre-
pared, four for the rounds of selection and one for
direct labelling of the proteins.
After exhaustive washing with PBS, magnetic beads
were blocked with 3% BSA in PBS (PBS-BSA) for 1 h at
room temperature. After washing, 100 μlo fM e h t aI
and II libraries, diluted 1:10 in PBS-BSA, pre-incubated
with magnetic beads to remove non-specific binders,
were added to the solution and incubated for 2 h at
room temperature. We performed four rounds of bio-
panning to get specific scFvs against GFP and Trx. Each
round of selection included a negative subtraction of the
phages against empty TALON™ Dynabeads
®. Beads
were washed 5 times with PBS-0.1% Tween during 2
min at room temperature and 40 rpm in a lab roller.
Prior to elution a final washing step with PBS was per-
formed to remove detergent from the media. Then,
phages were eluted with 100 μL of 0.1M glycine, pH 2.7
during 10 min at room temperature in a lab roller at 40
rpm. Finally, phages were neutralized with 20 μLo f1 M
Tris, pH 9.
The amplification of the phages during the four
rounds of biopanning was performed essentially as
described by Barbas et al. [11] with minor modifica-
tions. Briefly, 100 μL of eluted phages from the first
round of selection or 50 μL from the second and suc-
cessive rounds of selection were used to infect 2 mL
exponential phase XL1 Blue E. coli cells during 15 min
at room temperature. Then, 6 mL of SB medium (10 g
MOPS, 30 g of tryptone, 20 g of yeast extract in 1 L of
water at pH 7.0) containing 1.6 μL of 100 mg/mL car-
benicillin (Sigma) and 12 μL of 5 mg/mL tetracycline
were added to the cell culture and further incubated at
37°C for 1 h at 250 rpm. Then, 2.4 μLo f1 0 0m g / m L
carbenicillin (Sigma) were added to the cell culture for
an additional 1 h at 250 rpm at 37°C. Then, 1 mL
VCSM13 helper phage (10
12 to 10
13 pfu) was added to
the 8-mL cell culture together with 91 mL of pre-
warmed SB medium containing 46 μLo f1 0 0m g / m L
carbenicillin and 184 μL of 5 mg/ml tetracycline. The
media was further incubated at 300 rpm for 2 h at
37°C. Finally, 140 μLo f5 0m g / m Lk a n a m y c i nw a s
added to the medium and the solution was further
incubated overnight at 37°C.
The day after, the culture was centrifuged at 4000 rpm
for 15 min at 4°C. Supernatant containing phage sus-
pension was mixed with 4 g of PEG-8000 (Sigma) and 3
g of NaCl (Merck) until complete dissolution and, then,
was kept on ice for 30 min. Then, phages were centri-
fuged at 15000 g for 15 min and 4°C. Phages were
resuspended in 2 mL of 1% BSA (Sigma) in PBS. Then,
100 μL out of 2 mL phage solution were directly used
in subsequent rounds of biopanning as described above.
Production of human scFv microarrays
Ninety six colonies were randomly picked from the 3
rd
and 4
th round of biopanning against GFP and Trx. Indi-
vidual colonies were added to 96-well plates containing
200 μL of 2xTY, 100 μg/ml ampicillin and 1% glucose
and grown overnight at 37°C. Next day, cultures were
diluted 1:100 in 96-well plates containing 200 μLo f
2xTY, 100 μg/ml ampicillin and 0.1% glucose. IPTG was
added at 1 mM final concentration and cultures were
incubated overnight at 30°C. For scFv purification, cells
were spun down, resuspended in 100 μlT E S( 1 0m M
Tris-HCl pH 8.0, 0.1 mM EDTA, 150 mM NaCl, 20%
sucrose) and kept on ice for 30 min. The periplasmic
fraction was obtained by centrifugation at 1800 rpm for
10 min [41,57]. Then, scFv-containing periplasms were
diluted 1:2 in PBS, 0.1% Tween 20 (PBST) and directly
arrayed in duplicate onto FAST slides (Whatman). Anti-
T7 mouse monoclonal antibody (0.1 mg/mL, Novagen)
and 1:10 fold dilutions starting at 0.1 mg/mL of TA4
scFv, which contains a c-myc tag at the C-terminus
[ 4 0 ] ,w e r eu s e da sp o s i t i v ec o n t r o l sa n dP B S Ta sn e g a -
tive control.
FAST nitrocellulose slides (Schleicher & Schuell,
Whatman) were printed at 20°C and 45% of humidity
using a microarrayer (Omnigrid, GeneMachines) with 4
micro-spotting 70 μm diameter stealth pins with reser-
voir (TeleChem). Pins were fixed to dip once and pre-
spot 10 times before printing approximately 3 nL of
solution per spot. The separation between dots was 350
μm. Slides were kept overnight inside the arrayer at 20°
C and 75% of humidity for immobilizing the antibodies.
Nitrocellulose slides were stored at -20°C until use.
scFv microarray processing and data acquisition
Cell-free expressed GFP and Trx were labelled with a
647Alexa Fluor “Microscale Protein Labelling” kit (Invi-
trogen). Proteins attached to TALON™ Dynabeads
®
were eluted with 50 mM phosphate buffer, 0.3M NaCl,
150 mM imidazole pH 8.0, and extensively dialysed
against PBS. Purified proteins were lyophilised to con-
centrate before labelling.
Microarray slides were blocked with 4% skimmed milk
in PBS (MPBS) for 1 h at room temperature. Then,
either cell free AlexaFluor 647-labelled GFP or Trx (1
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c - m y ca n t i b o d y( 1μg/mL, Roche) in 4% MPBS were
added for 1 h at room temperature and incubated in
SecureSeal hybridization chambers (Grace Bio-Labs).
The microarrays were washed three times with PBST
during 10 min. For detecting AlexaFluor 647-GFP or
Trx, microarrays were air dried and directly scanned as
described below. For detecting bound GFP and Trx pro-
teins (or controls GFP-His6 and scFv-Trx-3xFlag), slides
were incubated with rabbit polyclonal anti-GFP (0.2 μg/
mL, Abcam) or monoclonal anti-Flag (10 μg/mL, Sigma)
for 1 h, washed and incubated with Alexa Fluor 555-
labeled goat anti-rabbit IgG (1μg/mL, Invitrogen) or
Alexa Fluor 555-labeled goat anti-mouse IgG (1μg/mL,
Invitrogen), respectively, for 1 h in the dark. For detect-
ing c-myc antibody, slides were incubated with Alexa
Fluor 555-labeled goat anti-mouse IgG antibodies (1 μg/
mL). After three 10 min washes with PBST, microarrays
were air dried and scanned with the ScanArray™ 5000
(Packard BioChip Technologies) using 635 nm and 532
nm lasers for Alexa 647 and Alexa 555, respectively.
The Genepix Pro 4.0 image analysis software was used
for quantification and analysis of the results.
Sequence analysis
Phagemide DNAs from individual scFv positive colonies
were amplified by PCR with the primers: pELB_forward,
5’-CATAATGAAATACCTATTGCCTA-3’ and c-
myc_reverse, 5’-CTTATTAGCGTTTGCCATT-3 [55].
Briefly, the cDNA encoding the scFvs was amplified
using an initial denaturation step at 94°C for 2 min, fol-
lowed by 30 cycles of 1 min at 94°C, 1 min at 55°C and
1 min at 72°C and a final step of 7 min at 72°C. Exonu-
clease I (USB) and shrimp alkaline phosphatase (USB)
were added to the PCR products to remove any con-
taminant. Sequencing was carried out in an ABI7002
DNA sequencer (Applied Biosystems).
ELISA and Western Blot analysis
For ELISA, flexible microtiter plates (Falcon, BD Bios-
ciences) were coated overnight with 0.3 μg/well of the
cell-free purified GFP or Trx. BSA or GST were used as
negative controls. After washing three times with PBS,
plates were blocked with 2% MPBS for 2 h at room
temperature. Then, either different dilutions of the
phage suspension or the periplasmic fractions were
tested in the presence of 2% MPBS for 2 h at 37°C.
After washing, peroxidase-labelled anti-M13 (1:5000
dilution in 2% MPBS) or anti-c-myc (1 μg/mL, Roche)
to detect the phages or scFvs, respectively, were added
for 1 h at 37°C. After washing, peroxidase reaction was
developed with 3,3’,5,5’-tetramethylbenzidine (TMB)
substrate (Sigma). The reaction was stopped with 1M
H2SO4 and the absorption measured at 450 nm.
For western blot analysis, proteins were transferred to
nitrocellulose membranes. GFP and Trx were detected
by using peroxidase-conjugated anti-His6 (0.3 μg/ml,
Roche). Alternatively, GFP-His6 or scFv-Trx control
proteins were detected with the corresponding scFvs at
100 ng/mL concentration. The signal was developed
using an anti-c-myc tag (1 μg/mL, Roche) followed by
peroxidase-conjugated anti-mouse IgG (0.2 μg/mL,
Sigma). All the incubations were for 1 h at 37°C. ECL
reagent was used for final detection.
Moreover, we have generated the fact sheets reporting
the Minimum Information
About a Protein Affinity Reagent (MIAPAR), where
we have included all the procedures and data reported
for the scFvs produced in this study against GFP (Addi-
tional File 1) and Trx (Additional File 2).
Additional material
Additional file 1: MIAPAR-compliant document for human anti-GFP
scFvs. The file includes the MIAPAR-compliant document presenting all
the information about the production of human anti-GFP scFvs
described in the manuscript.
Additional file 2: MIAPAR-compliant document for human anti-Trx
scFvs. The file includes the MIAPAR-compliant document presenting all
the information about the production of human anti-Trx scFvs described
in the manuscript.
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